Kymera Therapeutics to Present New Clinical Data from the Phase 1 Trial of STAT3 Degrader KT-333 at the ASH Annual Meeting
02 nov. 2023 09h00 HE
|
Kymera Therapeutics, Inc.
Abstract released today highlights safety, pharmacodynamic and clinical response data collected through July 10, 2023 cut-off Updated data to be presented at the American Society of Hematology (ASH)...
Kymera Therapeutics Announces Third Quarter 2023 Financial Results and Provides a Business Update
02 nov. 2023 07h00 HE
|
Kymera Therapeutics, Inc.
First patient dosed in KT-474/SAR444656 (IRAK4) Phase 2 HS clinical trial, generating a $40 million milestone payment from partner Sanofi; dosing of first patient in Phase 2 AD trial expected in the...
Kymera Therapeutics to Participate in Upcoming November Investor Conferences
01 nov. 2023 07h00 HE
|
Kymera Therapeutics, Inc.
WATERTOWN, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using...
Kymera Therapeutics Announces First Patient Dosed in Phase 2 Hidradenitis Suppurativa Clinical Trial of KT-474 (SAR444656), a First-in-Class, Investigational IRAK4 Degrader, Generating $40 Million Payment from Sanofi
27 oct. 2023 07h00 HE
|
Kymera Therapeutics, Inc.
WATERTOWN, Mass., Oct. 27, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using...
Kymera Therapeutics to Report Third Quarter 2023 Financial Results on November 2
26 oct. 2023 07h00 HE
|
Kymera Therapeutics, Inc.
WATERTOWN, Mass., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using...
Kymera Therapeutics Presents Preclinical Data Demonstrating Activity of MDM2 Degraders in Acute Myeloid Leukemia and Merkel Cell Carcinoma
16 oct. 2023 07h00 HE
|
Kymera Therapeutics, Inc.
Preclinical models highlight the potential of KT-253 as a monotherapy and combined with the standard of care agent venetoclax for the treatment of Acute Myeloid Leukemia (AML) MDM2 degraders...
Kymera Therapeutics Receives U.S. FDA Fast Track Designation for KT-333, a First-in-Class, Investigational STAT3 Degrader for the Treatment of Relapsed/Refractory Cutaneous T-Cell Lymphoma and Relapsed/Refractory Peripheral T-Cell Lymphoma
18 sept. 2023 07h00 HE
|
Kymera Therapeutics, Inc.
KT-333 Phase 1 oncology trial ongoing with an update including initial evaluation of its clinical antitumor activity in patients expected in the fourth quarter of 2023 Fast Track designation can...
Kymera Therapeutics to Participate in Upcoming September Investor Conferences
28 août 2023 07h00 HE
|
Kymera Therapeutics, Inc.
WATERTOWN, Mass., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small...
Kymera Therapeutics Announces Second Quarter 2023 Financial Results and Provides a Business Update
03 août 2023 07h00 HE
|
Kymera Therapeutics, Inc.
KT-474/SAR444656 (IRAK4) Phase 2 trials for both hidradenitis suppurativa (HS) and atopic dermatitis (AD) planned to start in 4Q23 by partner Sanofi Phase 1 oncology trials for KT-253 (MDM2),...
Kymera Therapeutics to Report Second Quarter 2023 Financial Results on August 3
27 juil. 2023 07h00 HE
|
Kymera Therapeutics, Inc.
WATERTOWN, Mass., July 27, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small...